3.0.0 3160 2025-12-05T09:10:18Z 2025-12-05T09:10:18Z House H HR 2023-05-09 118 https://www.congress.gov/bill/118th-congress/house-bill/3160 <pre>[Congressional Record Volume 169, Number 78 (Tuesday, May 9, 2023)][House]From the Congressional Record Online through the Government Publishing Office [<a href="https://www.gpo.gov">www.gpo.gov</a>]By Mr. RASKIN:H.R. 3160.Congress has the power to enact this legislation pursuantto the following:Article I, Section 8, clause 3.The single subject of this legislation is:Transparency of pharmaceutical research costs.[Page H2173]</pre> hsif00 Energy and Commerce Committee House Standing hsif14 Health Subcommittee Referred to 2023-05-12T15:45:56Z Referred To 2023-05-09T16:00:35Z hsba00 Financial Services Committee House Standing Referred To 2023-05-09T16:00:40Z 118 1476 S 2023-05-09 Read twice and referred to the Committee on Health, Education, Labor, and Pensions. Identical bill CRS 2023-05-12 hsif14 Health Subcommittee 1 House committee actions Referred to the Subcommittee on Health. Committee 2023-05-09 Referred to the Committee on Energy and Commerce, and in addition to the Committee on Financial Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. IntroReferral H11100 2 House floor actions hsba00 Financial Services Committee 2023-05-09 Referred to the Committee on Energy and Commerce, and in addition to the Committee on Financial Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. IntroReferral H11100 2 House floor actions hsif00 Energy and Commerce Committee 2023-05-09 Introduced in House IntroReferral Intro-H 9 Library of Congress 2023-05-09 Introduced in House IntroReferral 1000 9 Library of Congress R000606 Rep. Raskin, Jamie [D-MD-8] Jamie Raskin D MD 8 N S001208 Rep. Slotkin, Elissa [D-MI-7] Elissa Slotkin D MI 7 2023-06-12 False Health Administrative law and regulatory procedures 2023-07-14T12:30:57Z Department of Health and Human Services 2023-07-14T12:30:57Z Government information and archives 2023-07-14T12:30:57Z Manufacturing 2023-07-14T12:30:57Z Medical research 2023-07-14T12:30:57Z Prescription drugs 2023-07-14T12:30:57Z Research and development 2023-07-14T12:30:57Z Health 2023-05-18T17:00:28Z

00 2023-05-09 Introduced in House 2023-06-05T15:41:17Z <p><strong>Pharmaceutical Research Transparency Act of 2023</strong></p> <p>This bill requires the disclosure of costs associated with clinical trials and pharmaceutical research and development.</p> <p>Specifically, the National Institutes of Health must create a publicly available repository of cost data from certain clinical trials that test the efficacy of drugs, biological products, and devices in human subjects. For each applicable trial, the registry must, among other information, include the total and per patient cost of the trial, as well as costs for personnel, health care services, and other categories of expenditures. Information must be added to the registry within one year of the trial's completion.</p> <p>The bill also requires drug manufacturers to include their research and development expenditures for drugs and biological products in annual disclosures made to the Securities and Exchange Commission.</p>

Display Title 45 2024-07-24T15:22:20Z Short Title(s) as Introduced 101 2024-05-24T13:40:17Z Introduced in House IH Official Title as Introduced 6 2024-03-18T20:44:57Z Introduced in House IH Introduced in House 2023-05-09T04:00:00Z https://www.govinfo.gov/content/pkg/BILLS-118hr3160ih/xml/BILLS-118hr3160ih.xml 2023-05-12 Referred to the Subcommittee on Health. text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. Congressional Research Service, Library of Congress This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.